Follow us on Twitter
twitter icon@FreshPatents


Platelet patents

      

This page is updated frequently with new Platelet-related patent applications.




 Catalyst layer patent thumbnailCatalyst layer
A catalyst layer including: (i) a platinum-containing electrocatalyst; (ii) an oxygen evolution reaction electrocatalyst; (iii) one or more carbonaceous materials selected from the group consisting of graphite, nanofibres, nanotubes, nanographene platelets and low surface area, heat-treated carbon blacks wherein the one or more carbonaceous materials do not support the platinum-containing electrocatalyst; and (iv) a proton-conducting polymer and its use in an electrochemical device are disclosed.. .
Johnson Matthey Fuel Cells Limited


 Blood state analysis device, blood state analysis system, blood state analysis method, and storage device patent thumbnailBlood state analysis device, blood state analysis system, blood state analysis method, and storage device
A blood state analysis device (1) that analyzes a state of a blood sample, as used for clotting time testing, said blood sample comprising a plasma and at least one reagent, including a correction unit (11) configured to correct a measured blood coagulation evaluation result of the blood sample based on a relation between reference concentrations of the at least one reagent in plasma and reference blood coagulation evaluation results, the at least one reagent is an anticoagulation treatment releasing agent, a coagulation activator, an anticoagulant, a platelet activator, an antiplatelet drug, or a combination thereof and is present in the blood sample. For instance, such device (1) allows to correct blood clotting time results with respect to concentrations of an anti-coagulant drug present in the blood sample..
Sony Corporation


 Five-port blood separation chamber and methods of using the same patent thumbnailFive-port blood separation chamber and methods of using the same
Systems and methods are provided for separating blood into two or more separated blood components. The system includes a blood separation chamber with a single stage having five ports connected thereto.
Fenwal, Inc.


 Blood condition analysis device, blood condition analysis system, blood condition analysis method, and blood condition analysis program for causing computer to implement the method patent thumbnailBlood condition analysis device, blood condition analysis system, blood condition analysis method, and blood condition analysis program for causing computer to implement the method
Provided is a blood condition analysis device, for analyzing the condition of a blood sample having added thereto at least one kind of drug selected from the group consisting of anticoagulation treatment canceling agents, coagulation activators, anticoagulants, platelet activators, and antiplatelet agents, the device including a drug dosage control unit for controlling the dosage of the drug to be added to the blood sample on the basis of the hematocrit and/or hemoglobin content of the blood sample.. .

 Gas barrier fabric patent thumbnailGas barrier fabric
A gas barrier fabric is disclosed. The barrier fabric includes a fabric substrate.
Goodrich Corporation


 Low frequency ultrasonic vibration assisted bleeding-less surgical tool patent thumbnailLow frequency ultrasonic vibration assisted bleeding-less surgical tool
The present invention is a method for a bleedingless surgical tool that induces cavitation in blood vessel, tissue, and/or body fluid to facilitate platelet plug formation and induces cavitation together with a temperature rise to facilitate fibrin formation, inducing and enhancing blood clotting such that bleeding does not occur while cutting is in progress. The present invention is further a bleedingless surgical tool comprising a cutting portion of the surgical tool and an ultrasonic vibration generating portion forming by an ultrasonic alternating power source and an ultrasonic vibration transducer, which during cutting of live tissues and blood vessels induces cavitation in the blood vessel, tissue, and/or body fluid to facilitate platelet plug formation and induces cavitation and temperature rise to facilitate fibrin formation, inducing and enhancing blood clotting such that bleeding does not occur while the cutting is in progress..

 Compositions for treating wounds patent thumbnailCompositions for treating wounds
Novel compositions for treating wounds and promoting the healing thereof are described, including composition containing novel combinations of a carrier and recombinant platelet derived growth factor having fewer isoforms and enhanced biostability. Methods of treating wounds with novel therapeutic composition using dosing procedures leading to effective results with a minimal number of treatment applications are also described..

 Platelet rich plasma formulations patent thumbnailPlatelet rich plasma formulations
Compositions for platelet rich plasma (prp) and neutrophil-depleted prp are provided. Methods for treating ischemia damaged tissues by delivering a prp composition, in some embodiments a neutrophil-depleted prp composition to the damaged tissue are provided.

 Platelet-derived growth factor compositions and methods of use thereof patent thumbnailPlatelet-derived growth factor compositions and methods of use thereof
A method for promoting growth of bone, periodontium, ligament, or cartilage in a mammal by applying to the bone, periodontium, ligament, or cartilage a composition comprising platelet-derived growth factor at a concentration in the range of about 0.1 mg/ml to about 1.0 mg/ml in a pharmaceutically acceptable liquid carrier and a pharmaceutically-acceptable solid carrier.. .
Biomimetic Therapeutics, Llc


 Methods for treating wounds patent thumbnailMethods for treating wounds
Novel compositions for treating wounds and promoting the healing thereof are described, including composition containing novel combinations of a carrier and recombinant platelet derived growth factor having fewer isoforms and enhanced biostability. Methods of treating wounds with novel therapeutic composition using dosing procedures leading to effective results with a minimal number of treatment applications are also described..

Platelet-derived growth factor compositions and methods of use thereof

A method for promoting growth of bone, periodontium, ligament, or cartilage in a mammal by applying to the bone, periodontium, ligament, or cartilage a composition comprising platelet-derived growth factor at a concentration in the range of about 0.1 mg/ml to about 1.0 mg/ml in a pharmaceutically acceptable liquid carrier and a pharmaceutically-acceptable solid carrier.. .
Biomimetic Therapeutics, Llc

Platelet-derived growth factor compositions and methods of use thereof

A method for promoting growth of bone, periodontium, ligament, or cartilage in a mammal by applying to the bone, periodontium, ligament, or cartilage a composition comprising platelet-derived growth factor at a concentration in the range of about 0.1 mg/ml to about 1.0 mg/ml in a pharmaceutically acceptable liquid carrier and a pharmaceutically-acceptable solid carrier.. .
Biomimetic Therapeutics, Llc

Method and automated platelet identification within a whole blood sample from microscopy images

A method and apparatus for identifying platelets within a whole blood sample. The method includes the steps of: a) adding at least one colorant to the whole blood sample, which colorant is operable to tag platelets; b) disposing the blood sample into a chamber defined by at least one transparent panel; c) imaging at least a portion of the sample quiescently residing within the chamber to create one or more images; and d) identifying one or more platelets within the sample using an analyzer adapted to identify the platelets based on quantitatively determinable features within the image using a analyzer, which quantitatively determinable features include intensity differences..
Abbott Point Of Care, Inc.

Erythrocyte sedimentation inhibitor

The present invention addresses a problem in which, when examining blood properties in measurements of thrombus formation capacity and platelet function or the like, measurement data is changed as a result of sedimentation of blood in reservoirs during measurement. An erythrocyte membrane ion transport inhibitor, such as disodium 4,4′-dinitrostilbene-2,2′-disulfonate (dnds) or 4,4′-diisothiocyanatostilbene-2,2′-disulfonic acid (dids), is used to inhibit erythrocyte sedimentation, and accurate measurement data is obtained..
Fujimori Kogyo Co., Ltd.

Industrial lubricant including metal chalcogenide particles and phosphorus-based additive

An industrial lubricant composition including an oil base selected from the group consisting of vegetable oil, group i, group ii, group iii, group iv, group v and combinations thereof and a phosphorus-based non-chlorine additive. The industrial lubricant also includes at least one intercalation compound of a metal chalcogenide, a carbon containing compound and a boron containing compound, wherein the intercalation compound may have a geometry that is a platelet shaped geometry, a spherical shaped geometry, a multi-layered fullerene-like geometry, a tubular-like geometry or a combination thereof..
Nanotech Industrial Solutions, Inc.

Graphene reinforced polyethylene terephthalate

A composition and a method are provided for graphene reinforced polyethylene terephthalate (pet). Graphene nanoplatelets (gnps) comprising multi-layer graphene are used to reinforce pet, thereby improving the properties of pet for various new applications.
Niagara Bottling, Llc

Graphene reinforced polyethylene terephthalate

A composition and a method are provided for graphene reinforced polyethylene terephthalate (pet). Graphene nanoplatelets comprising a suitable initial surface area are added to a solvent for producing pet.
Niagara Bottling, Llc

Metal chelate compounds for binding to the platelet specific glycoprotein iib/iiia

The present invention is directed to compounds that bind to glycoprotein iib/iiia and can be used for diagnostic imaging, in particular magnetic resonance imaging of thrombi. The disclosed compounds enable the binding to glycoprotein iib/iiia receptor combined with an adequate imaging sensitivity..
Bayer Pharma Aktiengesellschaft

Method for controlling a blood component separation device including temporarily storing a component in a container

The object of the invention is to provide a blood separation device that can reduce the total time for drawing blood to obtain high-concentration platelet liquid, thereby reducing the binding time of the blood donor. The device includes a temporary storage bag (y2) (also serves as a buffy coat bag) which is a whole blood bag for storing whole blood drawn from a blood donor.
Terumo Kabushiki Kaisha

Film and coatings from nanoscale graphene platelets

A composite material includes a magnesium alloy and a layer consisting of nanoscale graphene platelets on at least a part of the surface of the magnesium alloy. A process for manufacturing such a composite material includes providing a magnesium alloy, providing nanoscale graphene platelets and applying the nanoscale graphene platelets to at least a part of the surface of the magnesium alloy..
Airbus Defence And Space Gmbh

Determination of platelet-mirnas in alzheimer's disease

The present invention relates to methods, kits and uses for determining platelet-mirnas in a from a platelet-comprising fraction derived from a whole blood sample from a subject affected or suspected to be affected by alzheimer's disease.. .
Hummingbird Diagnostics Gmbh

Colored platelets

A colored platelet including a substrate, an adhesion layer, a color pigment layer, and a secure layer and a method of producing the colored platelet are described. The disclosed colored platelet can provide a superior bright color effect in a coating composition.
Silberline Manufacturing Company, Inc.

4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase

Human lipoxygenases (loxs) are a family of iron-containing enzymes involved in catalyzing the oxidation of polyunsaturated fatty acids to provide the corresponding bioactive hydroxyeicosatetraenoic acid (hete) metabolites. These eicosanoid signaling molecules are involved in a number of physiologic responses such as platelet aggregation, inflammation, and cell proliferation.
Thomas Jefferson University

Wound healing composition

The present invention relates to compositions for use in pharmaceutical, cosmetic and cosmeceutical applications, particularly wound healing, including the treatment of lesions and burns. In particular, the present invention relates to compositions comprising platelet enriched plasma (prp) and stem cell conditioned medium (sc cm) for use in pharmaceutical, cosmetic and cosmeceutical applications such as wound healing..

Methods and devices for preparation of enriched biological fluids

The present disclosure relates to methods and apparatus for producing platelet rich plasma, bone marrow mononuclear cells, stromal vascular fraction from adipose tissue, and other concentrated or enriched biological fluids.. .
Arthrex, Inc.

Use of blood flow parameters to monitor or control the dosing of anti-platelet agents

The invention comprises a method of using blood flow parameters to optimize the therapeutic efficacy of an antiplatelet agent in the treatment of a disease or disorder associated with abnormal hemodynamic thrombogenicity in a subject.. .
Rheovector, Llc

Platelet activation and growth factor release using electric pulses

Methods and systems for releasing growth factors are disclosed. In certain embodiments, a blood sample is exposed to a sequence of one or more electric pulses to trigger release of a growth factor in the sample.
General Electric Company

Platelet activation and growth factor release using electric pulses

Methods and systems for releasing growth factors are disclosed. In certain embodiments, a blood sample is exposed to a sequence of one or more electric pulses to trigger release of a growth factor in the sample.
General Electric Company

Use of platelet rich plasma composition in the treatment of cardiac conduction abnormalities

Methods and kits for treating a cardiac arrhythmia using a platelet rich plasma (prp) composition are provided. Any type of arrhythmia may be treated using the prp composition.

Modulation of the physical interaction between platelets and the cell surface effecting cell proliferation

The growth and/or proliferation of mammalian cells are modulated by modulating the physical interaction between platelets (thrombocytes) and the surface of the cells. Sulfated polysaccharides, preferably glycosaminoglycans, can be used as a medicament for the inhibition of the physical interaction between the cell surface and platelets in the treatment of a medical disorder associated with unwanted cell growth and/or proliferation.
Cell Receptor Gmbh

Fluidics devices for individualized coagulation measurements and associated systems and methods

The present technology relates generally to fluidics devices for measuring platelet coagulation and associated systems and methods. In some embodiments, a fluidics device includes an array of microstructures including pairs of generally rigid blocks and generally flexible posts.
University Of Washington

Method and kit for determining the probability that a patient will develop a severe case of dengue

A method for determining, in vitro, the probability of a patient developing severe dengue, based on a blood sample, in which: a) the quantity in the blood sample of at least one marker, which is platelet factor 4, is determined; b) the quantity of platelet factor 4 determined in step a) is compared with a reference quantity of the marker obtained from a group of individuals who have been diagnosed with non-severe dengue, wherein, if the quantity of platelet factor 4 determined in step a) is less than the reference quantity established in step b), it is determined that the patient will develop severe dengue.. .
Biomerieux

Activators of cxcr3 for the treatment of angiopathies of the eye

The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of c-x-c chemokine receptor 3 (cxcr3). In some embodiments, the activator of cxcr3 is interferon-γ-inducible 10 kda protein (ip-10) or a fragment or variant thereof, such as a fragment comprising or consisting of the c-terminal α-helix of ip-10.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education

Patterned nano graphene platelet-based conductive inks

A nano graphene platelet-based conductive ink comprising: (a) nano graphene platelets (preferably un-oxidized or pristine graphene), and (b) a liquid medium in which the nano graphene platelets are dispersed, wherein the nano graphene platelets occupy a proportion of at least 0.001% by volume based on the total ink volume and a process using the same. The ink can also contain a binder or matrix material and/or a surfactant.

Highly conductive graphitic films

A flexible graphene platelet-filled composite film comprising a carbon or graphitic matrix and 1% to 99% weight fraction of graphene platelets dispersed in the matrix, wherein the graphene platelets are aligned along planar directions of said film and are selected from pristine graphene, oxidized graphene, reduced graphene oxide, fluorinated graphene, hydrogenated graphene, doped graphene, chemically functionalized graphene, or a combination thereof, and wherein the carbon or graphitic matrix is obtained by carbonizing a carbon precursor polymer at a carbonization temperature of at least 300° c. Or by carbonizing and graphitizing the carbon precursor polymer at a final graphitization temperature higher than 1,500° c., and the graphitic matrix comprises graphene layers that are substantially oriented parallel to one another with an inclination angle between two graphene layers less than 5 degrees.

Persevere-ii: redefining the pediatric sepsis biomarker risk model with septic shock phenotype

The methods disclosed herein relate to an improved tool incorporating platelet count into a multi-biomarker based outcome risk stratification model for evaluating mortality risk in pediatric patients having sepsis. The methods described here are useful for treating sepsis, for point of care clinical decision support, for stratifying septic shock patients based on baseline mortality risk, and for clinical trial design, among other uses..
Children's Hospital Medical Center

Activation of (na++k+)-atpase inhibits platelet aggregation and prevents thrombosis

Methods of inhibiting platelet aggregation using antibodies having binding specificity for the α subunit of the (na++k+)-atpase are provided, along with methods for inhibiting or preventing or treating thrombosis in a subject using such antibodies.. .

Compounds and methods for delivery of prostacyclin analogs

This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis.. .
United Therapeutics Corporation

Inhibition of platelet activation, aggregation and/or adhesion by hypothermia

A method for treating acute coronary syndromes (i.e., unstable angina or non-q-wave mi) or transient ischemic attacks in a human or animal patient by placing a heat exchange apparatus in the patient=s vasculature and using that heat exchange apparatus to cool the patient to a temperature (e.g. 30-36 degrees c.) at which platelet inhibition (i.e., inhibition of platelet activation and/or aggregation and/or adhesion) occurs.
Zoll Circulation Inc.

Electrode assembly for measurement of platelet function in whole blood

A platelet impedance measurement system including an electrode assembly allows for measurement of platelet function in blood. The assembly includes a substrate that acts as a substantially rigid base and includes an electrode.
Ca Casyso Ag

Synthetic platelets

Provided herein are various functionalized particles comprising a shell, dendritic linkers, and functional moieties. The dendrimer linkers allow very large numbers of functional moieties to be bound to the shell.
The Regents Of The University Of California



Platelet topics:
  • Growth Factor
  • Fibroblast
  • Nanoparticle
  • Autologous
  • Leukocytes
  • Circulation
  • Transforming Growth Factor
  • Therapeutical
  • Platelet Derived Growth Factor
  • Bone Morphogenetic Protein
  • Endothelial
  • Recombinant
  • Stem Cells
  • Respiratory System
  • Dispensing System


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Platelet for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Platelet with additional patents listed. Browse our RSS directory or Search for other possible listings.


    1.229

    file did exist - file did put2369

    3 - 1 - 51